<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095493</url>
  </required_header>
  <id_info>
    <org_study_id>STU-082021-075</org_study_id>
    <nct_id>NCT05095493</nct_id>
  </id_info>
  <brief_title>Oral Zinc Supplementation to Enhance Botulinum Neurotoxin Response</brief_title>
  <official_title>Oral Zinc Supplementation to Enhance Effects of Botulinum Neurotoxin Injection: an n of 1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Botulinum neurotoxin (BoNT) is injected into muscles for treatment of dystonia. BoNTs are&#xD;
      zinc proteases, and their enzymatic effect is reduced in the setting of low zinc. The study&#xD;
      hypothesis is that a large enough fraction of unselected dystonia patients receiving BoNT&#xD;
      injection have suboptimal zinc concentration in their tissues, and will experience improved&#xD;
      response to BoNT if the injection is preceded by oral zinc supplementation (OZS). OZS&#xD;
      consists of 50 mg of zinc acetate oral tablet each day for 7 days before injection. This is a&#xD;
      double blind placebo controlled cross-over study, randomized order placebo and OZS, in&#xD;
      patients at a neurology clinic on stable dose of BoNT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2013</start_date>
  <completion_date type="Actual">October 31, 2014</completion_date>
  <primary_completion_date type="Actual">October 31, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single site randomized placebo controlled trial, cross-over</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Pharmacy prepares vials labeled A and B, and reveals code to PI after data lock</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>End of study, week 48</time_frame>
    <description>Patient selects one of three options: My response to BoNT injection with bottle A tablets was overall better than with bottle B tablets; My response to BoNT injection with bottle B tablets was overall better than bottle A tablets; or Neither BoNT injection with bottle A or with bottle B tablets was overall better than the other</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>At study visits 3 and 4, which are 3 months after the BoNT injection cycles with intervention OZS or placebo</time_frame>
    <description>Unstructured interview soliciting side-effects in the interval since prior BoNT injection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Dystonia, Focal</condition>
  <arm_group>
    <arm_group_label>zinc, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received oral zinc acetate 50 mg tab each day for 7 days before scheduled BoNT injection. 3 months later participants received oral placebo (matching oral zinc) tablet each day for 7 days before scheduled BoNT injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, then zinc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received placebo tablet (matching oral zinc) each day for 7 days before scheduled BoNT injection. 3 months later participants received oral zinc acetate 50 mg tablet each day for 7 days before scheduled BoNT injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc Acetate</intervention_name>
    <description>50 mg tablet</description>
    <arm_group_label>placebo, then zinc</arm_group_label>
    <arm_group_label>zinc, then placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Zinc Acetate matched placebo tablet</description>
    <arm_group_label>placebo, then zinc</arm_group_label>
    <arm_group_label>zinc, then placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of the PI&#xD;
&#xD;
          -  Age 18-80&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  With an approved indication for BoNT such as dystonia or hemifacial spasm&#xD;
&#xD;
          -  Have received either two or three BoNT injection cycles within the prior 8 months&#xD;
&#xD;
          -  Prior two injection cycles length differed by no more than 2 weeks&#xD;
&#xD;
          -  Prior two injection cycles used same brand of BoNT and similar dose within 15%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concommitant use of penicillamine or cisplatin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Padraig E O'Suilleabhain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTSW</affiliation>
  </overall_official>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Padraig O'Suilleabhain</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

